Impact Of Cancer Prevalence On The Cancer Cachexia Market Emerges as a Core Driver of the Cancer Cachexia Market in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Cancer Cachexia Market Through 2025?
The market encompassing cancer cachexia has demonstrated robust expansion throughout the recent years, moving from a valuation of $2.47 billion in 2024 to an anticipated $2.6 billion in 2025, which represents a compound annual growth rate calculation of 5.3%; this upward trajectory observed during the past period is attributable to several factors, including a deepening comprehension of the underlying biology of cancer, the increasing incidence rates of the disease itself, a rising global demographic of older individuals, a heightened emphasis on care models centered around the patient, the proliferation of available therapeutic choices, and enhanced recognition among medical professionals.

What's the Projected Size of the Global Cancer Cachexia Market by 2029?
Anticipating robust expansion, the market dedicated to cancer cachexia is projected to $3.21 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 5.5% over the coming years; this upswing is fueled by heightened recognition surrounding cachexia treatment protocols, a continually increasing elderly demographic, the wider implementation of innovative treatment strategies, escalating healthcare spending, and supportive governmental policies, while key developments shaping this period involve intensified research and development activities, a broadening spectrum of available therapies, better identification rates, the uptake of new treatment methods, and progress within supportive care frameworks.

View the full report here:
https://www.thebusinessresearchcompany.com/report/cancer-cachexia-global-market-report

Top Growth Drivers in the Cancer Cachexia Industry: What's Accelerating the Market?
The expanding incidence of cancer is anticipated to be a major catalyst for the expansion of the cancer cachexia market moving ahead; this condition arises when aberrant cells multiply without restraint within the human body, creating tumors and interfering with typical physiological functions, and the surge in cancer cases stems from multiple elements such as shifts in lifestyle, environmental exposures, a growing elderly demographic, inherent genetic tendencies, enhanced diagnostic techniques enabling earlier identification, and heightened public awareness leading to greater uptake of medical consultation, all of which contribute to cancer cachexia being diagnosed and documented more regularly due to progress in medical innovation and a deeper comprehension of the disease and its related issues, allowing medical practitioners to better recognize cachexia indicators, thus permitting sooner therapeutic initiation; illustrating this trend, data from the Australian Bureau of Statistics, which is Australia's national statistics compilation body, showed that in December 2023, approximately 1.8 percent of people, translating to 456,200 persons, were recorded as having cancer in Australia during 2022, and concurrently, the US Federal government agency, the National Cancer Institute, projected in May 2024 that the United States would see an estimated 2,001,140 new cancer diagnoses in 2024, alongside an anticipated 611,720 fatalities from the illness, globally there were nearly 20 million new diagnoses and 9.7 million cancer-related deaths recorded in 2022, with projections suggesting that by 2040, yearly new cancer cases will climb to 29.9 million and related deaths to 15.3 million, underscoring how the rising occurrence of cancer is fundamentally fueling the market expansion for cancer cachexia treatments.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15527&type=smp

What Trends Will Shape the Cancer Cachexia Market Through 2029 and Beyond?
Leading firms within the cancer cachexia sector are actively creating novel therapeutic agents, exemplified by cachexia-specific monoclonal antibodies, with the goal of establishing a focused intervention for this condition that enhances physical mass, lean tissue retention, and the general well-being of individuals suffering from it; these cachexia monoclonal antibodies function by zeroing in on and blocking the underlying drivers of muscular atrophy and weight reduction. Demonstrating substantial progress, Pfizer Inc., a United States pharmaceutical enterprise, revealed in September 2024 the encouraging outcomes from its Phase 2 investigation of Ponsegromab, which is a monoclonal antibody designed to antagonize GDF-15, administered to cancer cachexia sufferers; this trial evidenced noteworthy gains in overall body weight alongside enhancements in muscle bulk, appetite stimulation, and physical engagement, with the highest efficacy observed at the 400 mg dosage level, prompting Pfizer to schedule the commencement of regulatory submission trials for Ponsegromab in 2025 to further explore its therapeutic promise for managing cancer cachexia.

What Are the Main Segments in the Cancer Cachexia Market?
The cancer cachexiamarket covered in this report is segmented -

1) By Therapeutics: Progestogens; Corticosteroids; Combination Therapies; Other Therapeutics
2) By Mechanism Of Action: Appetite Stimulators; Weight Loss Stabilizers; Other Mechanisms Of Actions
3) By Distribution Channel: Hospital Stores; Retail Pharmacy Stores; Online Pharmacies

Subsegments:
1) By Progestogens: Megestrol Acetate; Medroxyprogesterone Acetate; Hydroxyprogesterone Caproate
2) By Corticosteroids: Dexamethasone; Prednisolone; Methylprednisolone
3) By Combination Therapies: Progestogens + Corticosteroids; Progestogens + Anabolic Agents; Corticosteroids + Anabolic Agents
4) By Other Therapeutics: Anabolic Agents; Appetite Stimulants; Anti-inflammatory Drugs; Nutritional Supplements

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15527&type=smp

Which Top Companies are Driving Growth in the Cancer Cachexia Market?
Major companies operating in the cancer cachexia market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Novartis International AG, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals plc, Endo International plc, Aspen Pharmacare Holdings Limited, Lupin Limited, Mallinckrodt plc, Akorn Inc., Aeterna Zentaris, XBiotech Inc.

Which Regions Will Dominate the Cancer Cachexia Market Through 2029?
North America was the largest region in the cancer cachexia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer cachexia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15527

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.